scholarly journals Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes

2020 ◽  
Vol 11 ◽  
pp. 372-382 ◽  
Author(s):  
Alfredo Nuñez-Rivera ◽  
Pierrick G J Fournier ◽  
Danna L Arellano ◽  
Ana G Rodriguez-Hernandez ◽  
Rafael Vazquez-Duhalt ◽  
...  

There is an increasing interest in the use of plant viruses as vehicles for anti-cancer therapy. In particular, the plant virus brome mosaic virus (BMV) and cowpea chlorotic mottle virus (CCMV) are novel potential nanocarriers for different therapies in nanomedicine. In this work, BMV and CCMV were loaded with a fluorophore and assayed on breast tumor cells. The viruses BMV and CCMV were internalized into breast tumor cells. Both viruses, BMV and CCMV, did not show cytotoxic effects on tumor cells in vitro. However, only BMV did not activate macrophages in vitro. This suggests that BMV is less immunogenic and may be a potential carrier for therapy delivery in tumor cells. Furthermore, BMV virus-like particles (VLPs) were efficiently loaded with small interfering RNA (siRNA) without packaging signal. The gene silencing was demonstrated by VLPs loaded with siGFP and tested on breast tumor cells that constitutively express the green fluorescent protein (GPF). After VLP-siGFP treatment, GFP expression was efficiently inhibited corroborating the cargo release inside tumor cells and the gene silencing. In addition, BMV VLP carring siAkt1 inhibited the tumor growth in mice. These results show the attractive potential of plant virus VLPs to deliver molecular therapy to tumor cells with low immunogenic response.

2011 ◽  
Vol 308 (1) ◽  
pp. 23-32 ◽  
Author(s):  
Gengyun Wen ◽  
Michael A. Partridge ◽  
Bingyan Li ◽  
Mei Hong ◽  
Wupeng Liao ◽  
...  

2009 ◽  
Vol 58 (11) ◽  
pp. 1887-1896 ◽  
Author(s):  
Timothy E. Kute ◽  
Lori Savage ◽  
John R. Stehle ◽  
Jung W. Kim-Shapiro ◽  
Michael J. Blanks ◽  
...  

Pathobiology ◽  
2001 ◽  
Vol 69 (3) ◽  
pp. 120-126 ◽  
Author(s):  
Ayhan Bilir ◽  
Meric A. Altinoz ◽  
Melike Erkan ◽  
Vahit Ozmen ◽  
Adnan Aydiner

2020 ◽  
Vol 532 (4) ◽  
pp. 505-512
Author(s):  
Hideaki Ichihara ◽  
Keiji Kuwabara ◽  
Yoko Matsumoto

2020 ◽  
Author(s):  
Rica Boscencu ◽  
Radu Socoteanu ◽  
Gina Manda ◽  
Georgiana Vasiliu ◽  
Dumitru Lupuleasa ◽  
...  

2021 ◽  
Vol 14 (6) ◽  
pp. 521
Author(s):  
Nehal Gupta ◽  
Sanjay K. Srivastava

Triple-negative breast cancer (TNBC) is considered to be the most aggressive and malignant neoplasm and is highly metastatic in nature. In the current study, we investigated the anti-metastatic potential of atovaquone, a protozoal drug prescribed for Pneumocystis pneumonia. We showed that atovaquone induced apoptosis and reduced the survival of several aggressive metastatic TNBC cell lines including metastatic patient-derived cells by reducing the expression of integrin α6, integrin β4, FAK, Src, and Vimentin. In order to study the efficacy of atovaquone in suppressing metastasized breast tumor cells in brain and lungs, we performed three in vivo experiments. We demonstrated that oral administration of 50 mg/kg of atovaquone suppressed MDA-MB-231 breast tumor growth by 90% in lungs in an intravenous metastatic tumor model. Anti-metastatic effect of atovaquone was further determined by intracardiac injection of 4T1-luc breast tumor cells into the left ventricle of mouse heart. Our results showed that atovaquone treatment suppressed the growth of metastatic tumors in lungs, liver and brain by 70%, 50% and 30% respectively. In an intracranial model, the growth of HCC1806-luc brain tumors in atovaquone treated mice was about 55% less than that of control. Taken together, our results indicate the anti-metastatic effects of atovaquone in vitro and in vivo in various breast tumor metastasis models.


Sign in / Sign up

Export Citation Format

Share Document